Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Gross Margin: 2020-2025

Historic Gross Margin for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to 94.65%.

  • Apellis Pharmaceuticals' Gross Margin rose 1170.00% to 94.65% in Q3 2025 from the same period last year, while for Sep 2025 it was 88.85%, marking a year-over-year increase of 238.00%. This contributed to the annual value of 84.93% for FY2024, which is 31.00% down from last year.
  • As of Q3 2025, Apellis Pharmaceuticals' Gross Margin stood at 94.65%, which was up 2.47% from 92.37% recorded in Q2 2025.
  • Apellis Pharmaceuticals' 5-year Gross Margin high stood at 100.00% for Q1 2021, and its period low was 79.40% during Q1 2025.
  • For the 3-year period, Apellis Pharmaceuticals' Gross Margin averaged around 86.06%, with its median value being 86.40% (2023).
  • As far as peak fluctuations go, Apellis Pharmaceuticals' Gross Margin slumped by 1,404bps in 2023, and later soared by 1,170bps in 2025.
  • Quarterly analysis of 5 years shows Apellis Pharmaceuticals' Gross Margin stood at 99.92% in 2021, then crashed by 1,282bps to 87.09% in 2022, then slumped by 70bps to 86.40% in 2023, then plummeted by 562bps to 80.78% in 2024, then surged by 1,170bps to 94.65% in 2025.
  • Its Gross Margin was 94.65% in Q3 2025, compared to 92.37% in Q2 2025 and 79.40% in Q1 2025.